MRgFUS治疗中危前列腺癌:扩大消融/病灶体积比的作用
结果显示24个月活检达肿瘤学有效的患者ALVR约为复发者的两倍,而ALVR增大未增加尿控或勃起功能障碍风险。
要点
- 肿瘤学有效者的ALVR约为复发者的两倍(17 vs 8),提示消融范围需按病灶体积缩放。
- ALVR增大未显著增加新发勃起功能障碍或尿路症状,安全性可接受。
- 固定前列腺内切缘可能不足,阅片及治疗计划时应关注ALVR而非固定切缘。
核心结论
- 中危前列腺癌患者中,更高的ALVR与更优的2年肿瘤学结局相关,且未增加尿控或勃起功能障碍风险。
- 增加NPV占前列腺总体积比例并未改善肿瘤学结局。
研究设计与样本
- 研究类型为基于前瞻性采集数据的回顾性分析,属于2b期多中心MRgFUS试验。
- MRI可见病灶体积中位数为0.47 mL(IQR:0.20-0.95),周围无灌注体积中位数为6.9 mL(IQR:5.2-10.4)。
- 肿瘤学疗效以24个月活检时治疗区内无临床有意义前列腺癌(GGG≥2)来判定。
关键影像表现/征象
- 以MRI可见病灶体积为基础,用包绕病灶的前列腺无灌注体积定义消融体积与病灶体积之比。
- 肿瘤学有效者与复发者在24个月活检时的基线特征无显著差异。
诊断标准与关键数值
- 肿瘤学有效者ALVR为17,复发者ALVR为8,均值差8.8(95% CI:2.1,16,p=0.013),有效者约为复发者的两倍。
- 新发勃起功能障碍者与无新发勃起功能障碍者ALVR均值差为2.1(95% CI:-12,16,p=0.8)。
- 新发尿路症状者与无新发尿路症状者ALVR均值差为4.0(95% CI:-21,29,p=0.71)。
临床应用与阅片要点
- 在MRgFUS治疗计划中应重视按MRI可见病灶体积缩放ALVR,而非仅采用固定的前列腺内切缘。
- 解读术后无灌注区时,可结合ALVR评估消融覆盖是否充分。
局限性
- 本研究为回顾性解读前瞻性数据,原文未报告更多设计局限信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine which treatment parameters optimize focal therapy for intermediate-risk prostate cancer by balancing oncologic control with healthy tissue preservation, in a phase 2b multicenter trial of MRI-guided Focused Ultrasound (MRgFUS). Additionally, to assess the relationship of ablation volume relative to lesion volume with oncologic outcomes, urinary, and erectile function.
MATERIALS AND METHODS: In this retrospective interpretation of prospectively acquired data, the non-perfused volume (NPV) of prostate tissue encompassing the MRI-visible lesion volume defined the ablation-volume-to-lesion-volume ratio (ALVR). Oncologic efficacy was assessed as the absence of clinically significant (GGG ≥ 2) cancer in the treatment zone at 24-month biopsy. Associations between ALVR and outcomes were assessed using Student's t-tests. Baseline characteristics were compared using Kruskal-Wallis tests.
RESULTS: Eighty-nine men (mean age, 63 years ± 7) had MRI-visible lesions with a volume of 0.47 mL (IQR: 0.20-0.95), with a surrounding NPV of 6.9 mL (IQR: 5.2-10.4). Men achieving oncologic efficacy had twice the ALVR compared to those with recurrence at the treatment site (17 vs 8, mean difference 8.8, 95% CI: 2.1, 16, p = 0.013). Increasing NPV relative to total prostate volume did not improve oncologic outcomes. Baseline characteristics did not significantly differ between men with and without GGG ≥ 2 at 24-month biopsy. ALVR did not differ in men with new erectile dysfunction (mean difference in ALVR: 2.1, 95% CI: -12, 16, p = 0.8) or urinary symptoms (mean difference in ALVR 4.0, 95% CI: -21, 29, p = 0.71).
CONCLUSIONS: In patients with intermediate-risk prostate cancer, higher ALVR was associated with superior 2-year oncologic outcomes without increased risk of urinary or erectile dysfunction.
KEY POINTS: Question What treatment parameters optimize focal therapy for prostate cancer by balancing healthy tissue preservation with favorable oncologic outcomes? Findings Patients without residual cancer at 24-month biopsy had twice the ALVR of those with recurrence, with no adverse impact on erectile or urinary function. Clinical relevance While fixed intra-prostatic margins (e.g., 5 mm or 10 mm) are commonly prescribed in focal therapy, this study highlights the importance of scaling the ALVR in the treatment plan to achieve sufficient oncologic coverage.
引用
- Bitton, Vertosick, Khandwala, et al. Optimizing prostate cancer treatment with MR-guided focused ultrasound: the role of expanded ablation-to-lesion volume ratio. Eur Radiol. 2026. PMID: 41540208. doi:10.1007/s00330-025-12217-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。